Transport of Effector T cells and Nano-DC vaccine in Breast Cancer

新型冠状病毒SARS-CoV-2或新冠肺炎仅在美国就已感染100多万人，约6.3万人死亡(日期：2020年4月30日)。虽然人们对这种冠状病毒知之甚少，但已知新冠肺炎可引发以铁蛋白和d-二聚体升高为特征的病理性炎症，以及IL-2R、6、10和肿瘤坏死因子-α等促炎细胞因子，这表明死亡可能是由于过度炎症导致的器官衰竭。根据我们休斯顿卫理公会医院的观察和一份关于武汉患者的公开报告，感染新冠肺炎的癌症患者患重症和需要住院的风险增加了约3.5%。本行政补充资料旨在深入了解在霍尼韦尔医院接受试验性治疗措施的癌症和非癌症新冠肺炎患者的免疫应答，该试验已收到非常积极的临床结果：1-使用抗IL-6受体抗体tocilizumab(Actemra，Genentech，CA南旧金山)；以及2-应用单一捐赠者储存的骨髓间充质干细胞(MSC)治疗SARS-CoV-2诱导的急性呼吸衰竭。我们建议测定新冠肺炎感染患者在接受抗IL 6受体妥昔珠单抗或骨髓间充质干细胞治疗后的炎症相关标志物和细胞因子谱，并建立相关的免疫谱图来预测患者的资格和临床结果。我们团队准备进行这项研究是独一无二的，因为我们可以获得1000多份来自新冠肺炎癌症和非癌症(对照)患者的血液样本(血浆和黄褐色涂层细胞)。我们相信，这将有助于了解与受病毒感染影响的癌症患者的免疫反应相关的正在进行的过程，以及疾病的管理如何影响这种反应，并最终帮助开发感染新冠肺炎的癌症患者的免疫疗法。

The novel coronavirus SARS-CoV-2 or COVID-19 has infected over a million people with approximately 63K deaths in the United States alone (date: April 30, 2020). While little is known about this coronavirus, COVID-19 is known to initiate pathologic inflammation characterized by elevated ferritin and d-dimer, and proinflammatory cytokines such as interleukin (IL) -2R, 6, 10 and Tumor Necrosis Factor-alpha (TNF-?), suggesting that mortality might be due to organ failure driven by hyperinflammation. Cancer patients with COVID-19 infection are at about 3.5 times increased risk of developing severe cases and requiring hospitalization, as has been observed at our Houston Methodist Hospital (HMH) and a published report on patients in Wuhan, China. This administrative supplement is designed to gain in-depth insights onto the immune response of cancer vs. non-cancer COVID-19 patients undergoing pilot therapeutic interventions at HMH that has received very positive clinical outcomes: 1- the use of tocilizumab, an anti-IL-6 receptor antibody (Actemra, Genentech, South San Francisco, CA); and 2- a pilot study of applying Single Donor Banked Bone Marrow Mesenchymal Stromal Cells (MSC) for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure. We propose to determine the inflammation-related markers and cytokine profiles in COVID-19 infected patients following either anti-IL6 receptor tocilizumab antibody or MSC treatments and to establish correlative immune profiles to predict patient eligibility and clinical outcome. Our group is uniquely poised to conduct this study as we have access to more than a thousand samples of blood specimens (plasma and buffy coat cells) from COVID-19 cancer and non-cancer (control) patients. We believe this will help understand the ongoing processes related to both the immunological response in cancer patients affected with the viral infection and how the management of the disease affect that response and ultimately help develop immunotherapies in COVID-19 infected cancer patients.